Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Osteoporosis diagnostics in spotlight amid doubts over NHS self-assessments

This article was originally published in Clinica

Executive Summary

The strongest doubts yet have emerged over the UK NHS' ability to self-assess its observance of standards of care, after the National Osteoporosis Society (NOS) questioned the high compliance rates reported by trusts in its specialism. A main area of concern for the NOS is any delay in diagnostic scanning, which puts untreated patients at a high risk of joint or vertebral fractures.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel